DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

GlaxoSmithKline (NYSE: GSK)

company name or ticker
Company Photos
(Click to zoom)

3 Value Stocks Near 52-Week Lows Worth Buying

These three value stocks may have taken it on the chin recently, but they could be poised for a quick rebound.

Merck Buys Rights to Ebola Vaccine Candidate from NewLink - Analyst Blog

Rolling With Biotech's Regulatory Punches: Chen Lin

BioMarin Takes Aim at Sarepta

BioMarin's acquisition of Prosensa puts it in direct competition with Sarepta.

Merck obtains right to experimental Ebola vaccine

Stop Worrying About Ebola: This is a Much More Pressing Concern

Ebola may be garnering all of the headlines, but this infectious disease has been a contributing factor to the eighth leading cause of death in the U.S.

Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen

Sanofi Beats The Drum

Buy-Rated Dividend Stocks: Top 3 Companies: GSK, PBA, ENLK

GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?

Shares of healthcare giants GlaxoSmithKline and Sanofi have fallen hard this year, resulting in unusually high dividend yields for these two companies. Here is a look at which company offers the better opportunity for income investors moving forward.
See More Articles...